{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T05:30:09Z","timestamp":1765776609448,"version":"3.48.0"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      <jats:italic>\u03b2<\/jats:italic>\n                      -blockers (BB) are the cornerstone of treatment for heart failure with reduced ejection fraction (HFrEF). However, due to potential adverse effects, guidelines recommend starting with a low dose and gradually titrating upwards. Hypertensive patients with HFrEF tend to have better drug responsiveness and prognosis, but it remains unclear whether they can tolerate initial high-dose BB. Therefore, this study aims to assess the tolerance of this population to initial high-dose BB therapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective observational study included 307 hypertensive patients with HFrEF who initiated BB therapy and were admitted to the cardiology department at West China Hospital, Sichuan University. Patients\u2019 demographic and clinical information was collected through the electronic medical record (EMR) system. Patients were categorized into a high-dose group if their initial BB dose exceeded 1\/8 of the target dose, all other patients were assigned to the standard-dose group. Multivariate logistic forward regression analysis was performed to explore factors influencing the prescriptions of intial high-dose BB and adverse safety outcomes related to BB therapy during hospitalization, including bradycardia, hypotension, acute HF, wheezing requiring bronchodilator therapy, and BB dose reduction or cessation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Seventy patients (22.8%) were initially prescribed high-dose BB. Logistic forward regression analysis revealed that only coronary heart disease was negatively associated with the prescriptions of initial high-dose BB, with an odds ratio of 0.435 (95% CI: 0.247\u20130.763,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.004). Further logistic regression analysis demonstrated no independent association between the initial high-dose BB therapy and the occurrence of adverse safety outcomes, including bradycardia, hypotension, acute HF, wheezing requiring bronchodilator therapy, or BB dose reduction or discontinuation (all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&amp;lt;\u20090.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Prescriptions of initial high-dose BB in hypertensive patients with HFrEF were not associated with an increased incidence of adverse safety outcomes. These findings indicate that initial high-dose BB therapy could be a viable strategy for this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2025.1672940","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T05:25:36Z","timestamp":1765776336000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Initial high-dose \u03b2-blockers toleration with reduced ejection fraction heart failure of hospitalized hypertensive patients"],"prefix":"10.3389","volume":"12","author":[{"given":"Xinran","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangyu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yilin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Si","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1093\/cvr\/cvac013","article-title":"Global burden of heart failure: a comprehensive and updated review of epidemiology","volume":"118","author":"Savarese","year":"2023","journal-title":"Cardiovasc Res"},{"key":"B2","doi-asserted-by":"publisher","first-page":"631","DOI":"10.26599\/1671-5411.2024.06.008","article-title":"Heart failure in China: epidemiology and current management","volume":"21","author":"Hu","year":"2024","journal-title":"J Geriatr Cardiol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1002\/ehf2.13921","article-title":"Five-year mortality of heart failure with preserved, mildly reduced, and reduced ejection fraction in a 4880 Chinese cohort","volume":"9","author":"Chen","year":"2022","journal-title":"ESC Heart Fail"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e45719","DOI":"10.7759\/cureus.45719","article-title":"The pathophysiology and new advancements in the pharmacologic and exercise-based management of heart failure with reduced ejection fraction: a narrative review","volume":"15","author":"Narayan","year":"2023","journal-title":"Cureus"},{"key":"B5","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1080\/03007995.2024.2318002","article-title":"Heart failure management with \u0392-blockers: can we do better?","volume":"40","author":"de Oliveira","year":"2024","journal-title":"Curr Med Res Opin"},{"key":"B6","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/03007995.2024.2317433","article-title":"Safety and tolerability of \u0392-blockers: importance of cardioselectivity","volume":"40","author":"Marti","year":"2024","journal-title":"Curr Med Res Opin"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (Hfa) of the esc","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e003866","DOI":"10.1136\/bmjopen-2013-003866","article-title":"Barriers to accurate diagnosis and effective management of heart failure have not changed in the past 10 years: a qualitative study and national survey","volume":"4","author":"Hancock","year":"2014","journal-title":"BMJ Open"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e013459","DOI":"10.1136\/bmjopen-2016-013459","article-title":"Improving care for heart failure patients in primary care, Gps\u2019 perceptions: a qualitative evidence synthesis","volume":"6","author":"Smeets","year":"2016","journal-title":"BMJ Open"},{"key":"B10","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.hfc.2021.02.001","article-title":"Pathophysiology of heart failure with preserved ejection fraction","volume":"17","author":"Youn","year":"2021","journal-title":"Heart Fail Clin"},{"key":"B11","doi-asserted-by":"publisher","first-page":"784","DOI":"10.3390\/jcm11030784","article-title":"Cause of death in heart failure based on etiology: long-term cohort study of all-cause and cardiovascular mortality","volume":"11","author":"Spitaleri","year":"2022","journal-title":"J Clin Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/j.mcna.2025.04.010","article-title":"Heart failure with reduced ejection fraction","volume":"109","author":"Barkoudah","year":"2025","journal-title":"Med Clin N Am"},{"key":"B13","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1002\/ehf2.14214","article-title":"Treatment response in recent-onset heart failure with reduced ejection fraction: non-ischaemic vs. ischaemic aetiology","volume":"10","author":"Silverdal","year":"2023","journal-title":"ESC Heart Fail"},{"key":"B14","doi-asserted-by":"publisher","first-page":"6661","DOI":"10.3390\/ijms25126661","article-title":"Hypertension and heart failure: from pathophysiology to treatment","volume":"25","author":"Gallo","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B15","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.amjcard.2016.10.014","article-title":"Comparison of patient characteristics and course of hypertensive hypokinetic cardiomyopathy versus idiopathic dilated cardiomyopathy","volume":"119","author":"Bobbo","year":"2017","journal-title":"Am J Cardiol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"770239","DOI":"10.3389\/fphar.2021.770239","article-title":"Guideline adherence of \u0392-blocker initiating dose and its consequence in hospitalized patients with heart failure with reduced ejection fraction","volume":"12","author":"Zhou","year":"2021","journal-title":"Front Pharmacol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s11906-020-1017-9","article-title":"Pathophysiology of hypertensive heart disease: beyond left ventricular hypertrophy","volume":"22","author":"Nwabuo","year":"2020","journal-title":"Curr Hypertens Rep"},{"key":"B18","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.hfc.2019.09.001","article-title":"Hypertension and heart failure: prevention, targets, and treatment","volume":"16","author":"Di Palo","year":"2020","journal-title":"Heart Fail Clin"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1002\/ejhf.3108","article-title":"Blood pressure levels and adverse cardiovascular outcomes in heart failure: a systematic review and meta-analysis","volume":"26","author":"Seidu","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"B20","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1001\/jama.293.5.572","article-title":"Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis","volume":"293","author":"Fonarow","year":"2005","journal-title":"JAMA"},{"key":"B21","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.amjcard.2010.10.014","article-title":"Trials on the effect of cardiac resynchronization on arterial blood pressure in patients with heart failure","volume":"107","author":"Ather","year":"2011","journal-title":"Am J Cardiol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaf673","article-title":"Beta-blockers after myocardial infarction: effects according to sex in the reboot trial","author":"Rossello","year":"2025","journal-title":"Eur Heart J"},{"key":"B23","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1111\/j.1524-6175.2005.04273.x","article-title":"Early initiation of beta blockade in heart failure: issues and evidence","volume":"7","author":"Williams","year":"2005","journal-title":"J Clin Hypertens"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1672940\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T05:25:37Z","timestamp":1765776337000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1672940\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":23,"alternative-id":["10.3389\/fcvm.2025.1672940"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2025.1672940","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,15]]},"article-number":"1672940"}}